



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

(Stock Code: 1548)
(股份代號: 1548)

NOTIFICATION LETTER 通知函件

26 September 2022

Dear Non-registered holder ^(Note 1),

Genscript Biotech Corporation (the “Company”)
– Notice of Publication of 2022 Interim Report (“Current Corporate Communication”)

The English and Chinese versions of the Company’s Current Corporate Communications are available on the Company’s website at <https://www.genscript.com/announcements-circulars.html> and <https://www.genscript.com.cn/announcements-circulars.html> and the HKEXnews website of The Stock Exchange of Hong Kong Limited (the “HKEX”) at www.hkexnews.hk. You may access the Current Corporate Communication on the homepage of our website under heading “Investors” or by browsing through the HKEX’s website. You will require Adobe® Reader® to view the relevant documents.

If you want to receive a printed version of the Current Corporate Communications, please complete the Request Form on the reverse side and return it to the Company c/o Computershare Hong Kong Investor Services Limited (the “Share Registrar”) by using the mailing label at the bottom of the Request Form (no need to affix a stamp if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the Share Registrar is 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong. The Request Form may also be downloaded from the Company’s website at <https://www.genscript.com/announcements-circulars.html> and <https://www.genscript.com.cn/announcements-circulars.html> or the HKEXnews website at www.hkexnews.hk.

Please note that your instruction on the Request Form will apply to all future Corporate Communications ^(Note 2) of the Company to be sent to you until you notify the Share Registrar to the contrary or unless you have at any time ceased to have shareholdings in the Company.

Should you have any queries relating to any of the above matters, please call the Share Registrar’s telephone hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. Monday to Friday, excluding public holidays, or send an email to genscript.ecom@computershare.com.hk.

Yours faithfully,
For and on behalf of
Genscript Biotech Corporation
Mr. Meng Jiange
Chairman and Executive Director

Note: (1) This letter is addressed to Non-registered holders (“Non-registered holder” means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Request Form on the reverse side.

(2) Corporate Communications include but are not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

* For identification purposes only

各位非登記持有人 ^(附註 1)：

金斯瑞生物科技股份有限公司* (「本公司」)
– 2022 年中期報告 (「本次公司通訊」) 之發佈通知

本公司的本次公司通訊文件的中、英文版已上載於本公司網站 <https://www.genscript.com.cn/announcements-circulars.html> 及 <https://www.genscript.com/announcements-circulars.html> 及香港聯合交易所有限公司(「香港交易所」)披露易網站(www.hkexnews.hk)。閣下可在本公司網站主頁「投資者關係」一欄內或在香港交易所網站開啟並瀏覽本次公司通訊。閣下須使用 Adobe® Reader® 開啟有關文件。

如閣下欲收取本次公司通訊文件之印刷本，請填妥在本函背面的申請表格，並使用隨附之郵寄標籤寄回本公司經香港中央證券登記有限公司(「證券登記處」)(如在香港投寄，毋須貼上郵票；否則，請貼上適當的郵票)。證券登記處地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。申請表格亦可於本公司網站 (<https://www.genscript.com.cn/announcements-circulars.html> 及 <https://www.genscript.com/announcements-circulars.html>) 或香港交易所披露易網站(www.hkexnews.hk)內下載。

請注意閣下於申請表格上作出的指示將適用於日後發送予閣下之本公司所有公司通訊 ^(附註 2)，直至閣下通知證券登記處另外之安排或直至閣下在任何時候停止持有本公司股權。

如對本函內容有任何疑問，請致電證券登記處電話熱線(852) 2862 8688，辦公時間為星期一至五(公眾假期除外)上午 9 時正至下午 6 時正或電郵至 genscript.ecom@computershare.com.hk。

代表
金斯瑞生物科技股份有限公司*
主席及執行董事
孟建革 先生
謹啟

2022 年 9 月 26 日

附註：(1) 此函件乃向本公司之非登記持有人(「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，透過香港中央結算有限公司不時向本公司發出通知，希望收到公司通訊)發出。如果閣下已經出售或轉讓所持有之本公司股份，則無需理會本函件及所附申請表格。

(2) 公司通訊文件包括但不限於：(a)董事會報告、年度財務報表連同核數師報告及(如適用)財務摘要報告；(b)中期報告及(如適用)中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；及(f)委任代表表格。

* 僅供識別

GBCH-26092022-1(0)

Request Form 申請表格

To: Genscript Biotech Corporation (“Company”)
(Stock Code: 1548)
c/o Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen’s Road East,
Wanchai, Hong Kong

致： 金斯瑞生物科技股份有限公司*（「公司」）
（股份代號：1548）
經香港中央證券登記有限公司
香港灣仔皇后大道東 183 號
合和中心 17M 樓

I/We would like to receive all Corporate Communications[#] of the Company (“Corporate Communications”) in the manner as indicated below:

本人／我們希望以下列方式收取 貴公司之所有公司通訊文件[#]（「公司通訊文件」）：

(Please mark **ONLY ONE (X)** of the following boxes)

(請從下列選擇中，僅在其中一個空格內劃上「X」號)

to receive the **printed English version** of all Corporate Communications **ONLY**; **OR**
僅收取公司通訊文件之英文印刷本；或

to receive the **printed Chinese version** of all Corporate Communications **ONLY**; **OR**
僅收取公司通訊文件之中文印刷本；或

to receive both **printed English and Chinese versions** of all Corporate Communications.
同時收取公司通訊文件之英文及中文印刷本。

Name
姓名

Address
地址

Contact telephone number
聯絡電話號碼

Signature(s)
簽名

Date
日期

Notes 附註：

- Please complete all your details clearly.
請閣下清楚填妥所有資料。
- This letter is addressed to Non-registered holders (“Non-registered holder” means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications).
此函件乃向本公司之非登記持有人（「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，透過香港中央結算有限公司不時向本行發出通知，希望收到公司通訊）發出。
- Any form with more than one box marked(X), with no box marked(X), with no signature or otherwise incorrectly completed will be void.
如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確，則本表格將會作廢。
- The above instruction will apply to the Corporate Communications to be sent to you until you notify to the Company c/o Computershare Hong Kong Investor Services Limited to the contrary or unless you have at anytime ceased to have holdings in the Company.
上述指示適用於發送予閣下之所有公司通訊，直至閣下經香港中央證券登記有限公司通知本公司另外之安排或任何時候停止持有本公司的股份。
- For the avoidance of doubt, we do not accept any other instruction given on this Request Form.
為免存疑，任何在本申請表格上的額外指示，本行將不予處理。

[#] Corporate Communications include but are not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
公司通訊文件包括但不限於：(a) 董事會報告、年度財務報表連同核數師報告及（如適用）財務摘要報告；(b) 中期報告及（如適用）中期摘要報告；(c) 會議通告；(d) 上市文件；(e) 通函；及(f) 委任代表表格。

* For identification purposes only
僅供識別

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freepost No. 簡便回郵號碼：37

Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

當閣下寄回本申請表格時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry 查詢
Rate our service 評價
Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact